Milestones Over Sales: The Sanofi Partnership Now Drives Novavax’s Outlook (NASDAQ:NVAX)

Novavax, Inc. ( NVAX ) managed to report a 3Q25 GAAP EPS loss of –$1.25, missing estimates by $0.33. Revenue came in at $70.45 million, which actually beat expectations by $25.58 million despite falling 16.6% year over year. The company also reiteratedI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific fo ...